Kevin P. Charpentier
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kevin P. Charpentier has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- David J. Greenblatt
Tufts University School of Medicine, Boston, Massachusetts, USA
1 shared publication Jerold S. Harmatz
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA, U.S.A.
1 shared publicationJoseph W. Poku
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA, U.S.A.
1 shared publication- Joshua T. Cohen
Department of Surgery, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA
1 shared publication Lisa L. VON Moltke
Department of Pharmacology and Experimental Therapeutics, Tufts University School of Medicine, Boston, MA, U.S.A.
1 shared publication- Rachel E. Beard
Department of Surgery, Rhode Island Hospital, Warren Alpert Medical School of Brown University, Providence, RI, USA
1 shared publication
Latest Publications
- Open Access
- 31 May 2021
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 25 (2) , 242-250
Lymphopenia following pancreaticoduodenectomy is associated with pancreatic fistula formation
Joshua T. Cohen, Kevin P. Charpentier, Thomas J. Miner, William G. Cioffi, and Rachel E. Beard. Ann Hepatobiliary Pancreat Surg 2021;25:242-50. https://doi.org/10.14701/ahbps.2021.25.2.242
- 31 May 2021
- Published by The Korean Association of Hepato-Biliary-Pancreatic Surgery in Annals of Hepato-Biliary-Pancreatic Surgery
- Vol. 25 (2) , 242-250
Open AccessLymphopenia following pancreaticoduodenectomy is associated with pancreatic fistula formation
Joshua T. Cohen, Kevin P. Charpentier, Thomas J. Miner, William G. Cioffi, and Rachel E. Beard. Ann Hepatobiliary Pancreat Surg 2021;25:242-50. https://doi.org/10.14701/ahbps.2021.25.2.242
- 1 March 1997
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 18 (2) , 139-149
ALPRAZOLAM HYDROXYLATION BY MOUSE LIVER MICROSOMESIN VITRO: THE EFFECT OF AGE AND PHENOBARBITAL INDUCTION
The effects of age on hepatic microsomal enzyme induction were studied in male CD-1 mice. Six week old and 1 year old animals were treated with either phenobarbital (80 mg kg−1) or saline once daily for 3 d. Twenty-four hours after the last treatment, animals were sacrificed and livers were harvested. Hepatic microsomal fractions were isolated and incubated with alprazolam, a triazolobenzodiazepine metabolized by cytochrome P-450-3A isoforms in humans. Metabolites were identified and quantitated by HPLC. All microsomal preparations produced two principal metabolites (α-OH- and 4-OH-alprazolam) while microsomes from phenobarbital-treated animals also produced a third metabolite (α, 4-dihydroxyalprazolam). Vmax , Km , and intrinsic clearance (Vmax/Km ratio) for both α-OH- and 4-OH-alprazolam in the saline-treated control animals were not significantly different between age groups. Vmax and intrinsic clearance for both metabolites were more than three times greater in phenobarbital-treated animals than in the control mice (p in vitro study of liver microsomal preparations from male CD-1 mice does not delineate a mechanism for impaired alprazolam clearance in aging organisms in vivo. There is no evidence that age alters susceptibility to induction by phenobarbital. © 1997 by John Wiley & Sons, Ltd.
- 1 March 1997
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 18 (2) , 139-149
ALPRAZOLAM HYDROXYLATION BY MOUSE LIVER MICROSOMESIN VITRO: THE EFFECT OF AGE AND PHENOBARBITAL INDUCTION
The effects of age on hepatic microsomal enzyme induction were studied in male CD-1 mice. Six week old and 1 year old animals were treated with either phenobarbital (80 mg kg−1) or saline once daily for 3 d. Twenty-four hours after the last treatment, animals were sacrificed and livers were harvested. Hepatic microsomal fractions were isolated and incubated with alprazolam, a triazolobenzodiazepine metabolized by cytochrome P-450-3A isoforms in humans. Metabolites were identified and quantitated by HPLC. All microsomal preparations produced two principal metabolites (α-OH- and 4-OH-alprazolam) while microsomes from phenobarbital-treated animals also produced a third metabolite (α, 4-dihydroxyalprazolam). Vmax , Km , and intrinsic clearance (Vmax/Km ratio) for both α-OH- and 4-OH-alprazolam in the saline-treated control animals were not significantly different between age groups. Vmax and intrinsic clearance for both metabolites were more than three times greater in phenobarbital-treated animals than in the control mice (p in vitro study of liver microsomal preparations from male CD-1 mice does not delineate a mechanism for impaired alprazolam clearance in aging organisms in vivo. There is no evidence that age alters susceptibility to induction by phenobarbital. © 1997 by John Wiley & Sons, Ltd.